DE69120500T2 - Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung - Google Patents

Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung

Info

Publication number
DE69120500T2
DE69120500T2 DE69120500T DE69120500T DE69120500T2 DE 69120500 T2 DE69120500 T2 DE 69120500T2 DE 69120500 T DE69120500 T DE 69120500T DE 69120500 T DE69120500 T DE 69120500T DE 69120500 T2 DE69120500 T2 DE 69120500T2
Authority
DE
Germany
Prior art keywords
alkyl group
substituted alkyl
carbon
aryl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69120500T
Other languages
English (en)
Other versions
DE69120500D1 (de
Inventor
Koichi Kojima
Hitoshi Kurata
Hiroyoshi Horikoshi
Takakazu Hamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of DE69120500D1 publication Critical patent/DE69120500D1/de
Application granted granted Critical
Publication of DE69120500T2 publication Critical patent/DE69120500T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
DE69120500T 1990-10-29 1991-10-29 Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung Expired - Fee Related DE69120500T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29140190 1990-10-29

Publications (2)

Publication Number Publication Date
DE69120500D1 DE69120500D1 (de) 1996-08-01
DE69120500T2 true DE69120500T2 (de) 1997-02-27

Family

ID=17768420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69120500T Expired - Fee Related DE69120500T2 (de) 1990-10-29 1991-10-29 Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung

Country Status (20)

Country Link
US (1) US5302621A (de)
EP (1) EP0484094B1 (de)
JP (1) JPH0819151B2 (de)
KR (1) KR0134570B1 (de)
CN (2) CN1053672C (de)
AT (1) ATE139783T1 (de)
AU (1) AU640279B2 (de)
CA (1) CA2054368C (de)
CZ (1) CZ279312B6 (de)
DE (1) DE69120500T2 (de)
DK (1) DK0484094T3 (de)
ES (1) ES2091299T3 (de)
GR (1) GR3020483T3 (de)
HK (2) HK1005456A1 (de)
HU (2) HU218667B (de)
IE (1) IE76452B1 (de)
IL (1) IL99889A (de)
PT (1) PT99371B (de)
RU (1) RU2070204C1 (de)
ZA (1) ZA918570B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
ES2118222T3 (es) * 1991-12-20 1998-09-16 Glaxo Wellcome Inc Inhibidores de 5-alfa-testosterona reductasa.
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
EP0725074A3 (de) * 1992-04-20 1996-11-20 Sankyo Co Verbindungen zur Verwendung also Zwischenprodukte zur Herstellung von Androst-3,5-dien-3-carboxy-Derivaten
EP0641209A4 (de) * 1992-05-20 1995-08-23 Merck & Co Inc Neue 17-ester-, amid- und ketonderivate von 3-oxo-4-azasteroiden als 5-alpha-reduktaseinhibitoren.
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
WO1995012398A1 (en) * 1993-11-04 1995-05-11 Merck & Co., Inc. 7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5693810A (en) * 1992-10-06 1997-12-02 Merck & Co., Inc. 17 β-carboxanilides of 4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
AU6427194A (en) * 1993-04-02 1994-10-24 Ciba-Geigy Ag Aza-androstane-17beta -carboxamides
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
IT1271325B (it) * 1994-12-23 1997-05-27 Poli Ind Chimica Spa Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
CN1072679C (zh) * 1995-07-30 2001-10-10 重庆医科大学 一种氮杂甾体化合物、制备及其用途
USRE39056E1 (en) * 1995-09-15 2006-04-04 Merck & Co, Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
AU707324B2 (en) * 1995-09-15 1999-07-08 Merck & Co., Inc. 4-azasteroids for treatment of hyperandrogenic conditions
ATE208631T1 (de) * 1996-02-05 2001-11-15 Sankyo Co 5-alpha reductase inhibierende zusammenstellung zur oralen verabreichung, verfahren zur herstellung und deren verwendung
US6093722A (en) * 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
EP0963998B1 (de) * 1997-02-26 2004-05-06 Sankyo Company Limited Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DK0998930T3 (da) * 1997-07-29 2004-04-26 Sankyo Co Azasteroidforbindelser til behandling af alopecia, hirsutisme og seborrhea
US6187925B1 (en) * 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
CN1784236A (zh) * 2003-05-07 2006-06-07 麦克公司 雄激素受体调节剂及其使用方法
CN100528168C (zh) * 2003-06-30 2009-08-19 麦克公司 作为雄激素受体调节剂的17-乙酰氨基-4-氮杂甾类衍生物
JP2007521293A (ja) * 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
EP1660184A4 (de) * 2003-06-30 2008-05-14 Merck & Co Inc 17-acetamido-4-azasteroid-derivate als androgen-rezeptor-modulatoren
US20080125403A1 (en) * 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US20090123571A1 (en) * 2005-03-25 2009-05-14 Alan Meehan Method of treating men with testosterone supplement and 5alpha-reductase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4179453A (en) 1978-04-13 1979-12-18 Merck & Co., Inc. Process for preparing 17β-carboxy-5-androsten-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4760071A (en) 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids

Also Published As

Publication number Publication date
HK1005456A1 (en) 1999-01-08
JPH0819151B2 (ja) 1996-02-28
HU211642A9 (en) 1995-12-28
CN1062145A (zh) 1992-06-24
CN1053672C (zh) 2000-06-21
JPH0532693A (ja) 1993-02-09
CS326991A3 (en) 1992-05-13
DK0484094T3 (da) 1996-10-28
PT99371B (pt) 1999-04-30
HUT59417A (en) 1992-05-28
GR3020483T3 (en) 1996-10-31
DE69120500D1 (de) 1996-08-01
IE76452B1 (en) 1997-10-22
IE913747A1 (en) 1992-05-22
ATE139783T1 (de) 1996-07-15
ES2091299T3 (es) 1996-11-01
KR920008063A (ko) 1992-05-27
CA2054368C (en) 2001-10-02
AU640279B2 (en) 1993-08-19
CN1209319A (zh) 1999-03-03
US5302621A (en) 1994-04-12
PT99371A (pt) 1992-09-30
IL99889A (en) 1995-06-29
KR0134570B1 (ko) 1998-04-14
HU913396D0 (en) 1992-01-28
RU2070204C1 (ru) 1996-12-10
HU218667B (hu) 2000-10-28
EP0484094B1 (de) 1996-06-26
HK1017274A1 (en) 1999-11-19
AU8682191A (en) 1992-04-30
ZA918570B (en) 1992-08-26
CA2054368A1 (en) 1992-04-30
EP0484094A2 (de) 1992-05-06
CN1072935C (zh) 2001-10-17
CZ279312B6 (cs) 1995-04-12
IL99889A0 (en) 1992-08-18
EP0484094A3 (en) 1993-07-14

Similar Documents

Publication Publication Date Title
DE69120500D1 (de) Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung
DE3881246T2 (de) Durch Benzhydryl N-substituierte heterocyclische Derivate, ihre Herstellung und ihre Verwendung.
DE69311837D1 (de) Steroide zur Behandlung von Prostatisch-Hypertrophe, ihre Herstellung und Verwendung
HUT50337A (en) Process for producing benzoxazine derivatives and pharmaceutical compositions comprising the compounds
HU905000D0 (en) Process for producing compounds suitable for treatment of gastric ulcer
FI912733A (fi) Menetelmä terapeuttisesti käyttökelpoisten /(1-aryylipyrrolidin-2-yyli)metyyli/piperatsiinijohdannaisten valmistamiseksi
DE69108587T2 (de) Verfahren und Zwischenprodukte zur Herstellung von optisch aktiven Chromanderivaten.
DE69327092T2 (de) Optisch aktives 1-phenylpyrrolidonderivat und dessen herstellung
HUP0000298A2 (hu) Eljárás aril-béta-diketon-, aril-pirimidin-keton-származékok és növényvédőszerek közbenső termékeinek előállítására
ATE100105T1 (de) Physiologisch aktive substanz fa-4283, derivate und ihre herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee